Pathomics Health and MAHSA Health sign MOU to launch Joint Centre for Research and Diagnostics for Precision Wellness and Clinical Research
Pathomics Health and MAHSA Health sign MOU to launch Joint Centre for Research and Diagnostics for Precision Wellness and Clinical Research
Minggu, 01 Januari 2023 | 20:51
KUALA LUMPUR, MALAYSIA -
Media OutReach - 30 December 2022 -Pathomics
Health, an organisation with a mission to provide accessible advanced
clinical diagnostics, has signed a Memorandum of Understanding (MoU)
with MAHSA Health to set up a Joint Centre for Research and Diagnostics
Services for Precision Wellness and Clinical Research at MAHSA Avenue.
The collaboration focuses on health and wellness screening with MAHSA
Health to optimise the wellbeing of individuals in Malaysia. Clinical
research will also be part of the partnership to further support
clinicians in their clinical care for patients across the MAHSA Health's
network of hospitals and clinics.
Combined expertise from both parties to make a significant impact on the
health and wellness of MAHSA Health's patients and cement the Joint
Centre's position as a Centre of Excellence for genomics to support
MAHSA Health in its advancement of health care services, research, and
innovation in ASEAN.
The changing lifestyles of the affluent middle-class lead to the disease
burden shifting from communicable diseases to non-communicable diseases
(NCDs) such as diabetes, cardiovascular disease, and cancer. As the
middle class becomes more aware of NCDs, there is a higher demand for
health check-ups and more effective diagnostics. With the use of
genomics testing advancement, individuals can now better uncover their
underlying risks profile to NCDs and take more proactive actions to
better manage their health.
For the past 10 years, cardiovascular disease (CVD) is among the leading
causes of death and morbidity in Malaysia . CVDs ranked first among the
ten principal causes of death in government hospitals (21.65%) and
ranked second in private hospitals (23.79%). While elderly is at risk of
developing CVDs, studies suggest that 1 in 5 heart attack patients are
younger than 40 years old. It is a myth that heart attacks only occur to
the old. Young adults should take proactive care of their health.1
Malaysia has one of the highest incidences of diabetes in the world.
According to the Malaysian 2019 national survey report, for ≥18 years
old age group, 3.6 million adults had diabetes, 49% (3.7 million) cases
were undiagnosed. It is estimated that diabetes can affect 7 million of
Malaysian adults, posing a major public health risk with a diabetes
prevalence of 31.3%.
2
Cancer is among the most common causes of deaths in Malaysia. Most cases
are only discovered at late stages resulting in poor therapy outcomes.
Rising direct and indirect costs of cancers impact on both the patient
and family. Approximately 45% of Malaysian cancer survivors spend over
30% of their household income for cancer care within the first year of
diagnosis. Early diagnosis of cancer can lead to a better likelihood of
effective treatment which in turn can increase the chances of survival,
less morbidity and less therapy costs.3
In 2020, 49,000 new cancer cases were estimated in Malaysia and
projected to rise to more than 66,000 per year by 2030. Approximately
50% of total cancer cases are due to breast, colorectal and lung cancers
in Malaysia. The leading causes of death for Malaysian women suffering
from cancer is breast and cervical cancer. The screening uptake and
frequency for breast, cervical, colorectal, and prostate cancers can be
better. The poor response to cancer screening can be due to a lack of
awareness on the available screening methods, support from family
members and family doctors.
"With the advancement of medical science, everyone should have access to
precision wellness and be empowered to lead heathier lifestyle and
better therapy outcomes with early interventions. The genomics profiling
test is a start for an individual to better understand one's health
risks profile for Cardiovascular, Cancer and Diabetes. We have a network
of healthcare professionals who will support those with high risk of
NCD to take proactive family planning measures, lifestyle changes to
better lower their risks. With the diverse health screening tests
options, it also acts as a compass for family physicians to personalise
health screening tests to better meet their patients' unique health
profile. " Michael Tan, Director of Pathomics Health.
MAHSA Health Sdn Bhd is a Malaysia-grown company, part of MAHSA Group of
Companies, which is determined to be a revolutionary leader in
healthcare. Since its inception in 2017, MAHSA Health has been striving
to be in the forefront of primary healthcare, focusing on family health
and wellness.
Pathomics Health focuses on advanced precision medicine diagnostics
& digital healthcare solutions–in particular, but not limited to
cancer. Since 2016, Pathomics Health has been driving excellence to
unlock actionable genomics insights to enhance patient care. Pathomics
Health forged its first public private partnership with University of
Malaya in 2016. In 2021, Pathomics Health was appointed by Qiagen as its
preferred laboratory outsourcing next generation sequencing research
solutions partner for ASEAN markets. In 2022, Pathomics Health sets up
its clinical diagnostics and research facilities in Singapore, focusing
on Infectious Diseases and Oncology and hereby expanding its operations
from Malaysia. Pathomics Health supports the acceleration of healthcare
and life science research in ASEAN markets by providing outsourcing
research testing services in addition to its clinical diagnostics
services. In 2022, Singviva, an insurtech partner of MY IRC Sdn Bhd, has
appointed Pathomics Health as its sole
genomics risk profiling diagnostics lab partner for their policy holders. To find out more about Pathomics Health's genomics profiling tests, visit
pathgene.asia.
With its latest collaboration with MAHSA, Pathomics health will provide
the Malaysian public and medical tourists visiting Malaysia access to
its advance health screening tools beyond
genomics profiling tests
services offered across MAHSA health network of primary care clinics
and hospital. Pathomics health and MAHSA are committed to improve
primary healthcare and push the frontiers of clinical research and
advanced digital healthcare solutions in precision wellness, infectious
diseases screening and pharmacogenomics.
"With the collaboration with Pathomics Health, we look forward to
advancing primary healthcare in the era of precision wellness for our
patients for better health outcomes. We are excited of this opportunity
to make a difference in the combat of Cancer, Cardiovascular and
Diabetes for Malaysians. " Datin Dr. Maya Kumutha , Chief Executive
Officer of MAHSA Health